Dennis Ding
Stock Analyst at Jefferies
(0.36)
# 4,173
Out of 4,962 analysts
13
Total ratings
22.22%
Success rate
-10.64%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INDV Indivior | Assumes: Buy | $20 | $24.01 | -16.70% | 1 | Jul 22, 2025 | |
| MLYS Mineralys Therapeutics | Initiates: Hold | $15 | $14.71 | +1.97% | 1 | Jun 11, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $30.06 | +82.97% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.78 | +350.70% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $26.62 | +31.48% | 1 | Sep 20, 2024 | |
| FOLD Amicus Therapeutics | Initiates: Buy | $18 | $7.48 | +140.64% | 1 | Sep 6, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $3.50 | +100.00% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $4.83 | +24.22% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $6.92 | +261.27% | 1 | May 7, 2024 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $68.77 | -68.01% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $24.70 | -2.83% | 1 | Dec 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $11.64 | -14.09% | 1 | Oct 26, 2021 |
Indivior
Jul 22, 2025
Assumes: Buy
Price Target: $20
Current: $24.01
Upside: -16.70%
Mineralys Therapeutics
Jun 11, 2025
Initiates: Hold
Price Target: $15
Current: $14.71
Upside: +1.97%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $30.06
Upside: +82.97%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.78
Upside: +350.70%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $26.62
Upside: +31.48%
Amicus Therapeutics
Sep 6, 2024
Initiates: Buy
Price Target: $18
Current: $7.48
Upside: +140.64%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $3.50
Upside: +100.00%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $4.83
Upside: +24.22%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $6.92
Upside: +261.27%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $68.77
Upside: -68.01%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $24.70
Upside: -2.83%
Oct 26, 2021
Initiates: Buy
Price Target: $10
Current: $11.64
Upside: -14.09%